• Keros Therapeutics posted a net loss of $23.7 million for the quarter ended March 31, 2026, swinging from net income of $148.5 million a year earlier.
• Revenue fell 99.83% to $367,000, driven by a drop in license revenue to no revenue from $195.36 million a year earlier.
• Research and development expense decreased 66.96% to $16.1 million, reflecting lower elritercept- and cibotercept-related spending as activities transitioned to Takeda and a terminated Phase 2 trial reduced costs.
• Cash and cash equivalents totaled $281.5 million at March 31, 2026, with runway projected into the first half of 2028.
• Rinvatercept Phase 2 trial in Duchenne muscular dystrophy expected to start in the third quarter of 2026, with initial data anticipated in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-26-000030), on May 14, 2026, and is solely responsible for the information contained therein.